Immune-hormonal imbalance in chemical cancerogenesis

Cover Page

Cite item

Full Text

Abstract

The present article deals with experimental and clinical aspects of immuno-hormonal interactions in chemical carcinogenesis i.e., formation of DNA-adducts with chemical carcinogens as a trigger of tumor initiation; synthesis of specific antibodies as markers of human exposure to environmental carcinogens; immunomodulation of chemical carcinogenesis by the specific antibodies in experimental studies; interactions of antibodies against environmental carcinogens with endogenous steroid hormones in human carcinogenesis; immunological interference and inversion of immuno-hormonal interactions by the action of antibodies against environmental carcinogens; immune stimulation of tumor progression in cancer patients. It is shown that antibodies specific to estradiol and progesterone participate in regulation of serum estradiol and progesterone levels in healthy women. Excessive production of antibodies against benzo[a]pyrene is associated with impaired physiological balance between the levels of antibodies to estradiol and progesterone, thus causing disturbed physiological balance between serum estradiol and progesterone. Immuno-hormonal imbalance promotes tumor initiation, its growth and progression. The new approaches to the personalized cancer immunoprediction and immune prevention are discussed. Coordinated synthesis of antibodies against benzo[a]pyrene and estradiol seems to reflect production of DNA-adducts with genotoxic metabolic effects of these compounds manifesting as synergistic carcinogenic effects upon the target cells. Hence, simultaneously increased levels of serum antibodies against benzo[a]pyrene and estradiol in healthy people may be considered an immunological marker of high oncological risk and an reason to use of new immunoprotective tools against polycyclic aromatic hydrocarbons and phytoestrogens. However, ability of these antibodies to raise the blood serum levels of environmental carcinogens and endogenous estradiol, as shown in vitro and in vivo, excludes the opportunity for active cancer immune prevention. Usage of anticarcinogen vaccines aimed for induction of protective secretory antibodies is likely to further increase high levels of procarcinogenic serum antibodies against benzo[a]pyrene and estradiol, followed by additional enhancement of immuno-hormonal imbalance and promotion of carcinogenesis. Development of probiotics transduced with genes encoding human antibodies against environmental carcinogens may present an alternative approach to cancer immune prevention. The antibodies produced by such probiotics would bind appropriate carcinogens and prevent their invasion into the organism, thus inhibiting emergence of DNA-adducts and suppressing synthesis of specific autoantibodies that may promote carcinogenesis. The aim is to substantiate the concept of immuno-hormonal imbalance for the carcinogen-induced hormone-dependent tumors.

About the authors

Andrew N. Glushkov

Institute of Human Ecology, Federal Research Center of Coal and Coal Chemistry, Siberian Branch of Russian Academy of Sciences

Author for correspondence.
Email: stellamun@yandex.ru
ORCID iD: 0000-0002-8560-6719

PhD, MD (Medicine), Professor, Chief Research Associate, Laboratory of Immunogenetics

Russian Federation, 650065, Kemerovo, Leningradsky ave., 10

References

  1. Высоцкая И.В., Летягин В.П., Шабанов М.А., Кирсанов В.Ю., Ким Е.А., Левкина Н.В. Актуальные вопросы канцерогенеза // Клиническая онкогематология, 2019. Т. 12, № 1. С. 101-106. [Vysotskaya I.V., Letyagin V.P., Shabanov M.A., Kirsanov V.Yu., Kim E.A., Levkina N.V. Current issues in carcinogenesis. Klinicheskaya onkogematologiya = Clinical Oncohematology, 2019, Vol. 12, no. 1, pp. 101-106. (In Russ.)]
  2. Глушков А.Н. Клиническая иммунохимия канцерогенеза: новые задачи и перспективы // Российский иммунологический журнал, 2013. Т. 7 (16), № 1. С. 27-34. Glushkov A.N. The immunochemistry on carcinogenesis: the new tasks and perspectives. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2013, Vol. 7 (16), no. 1, pp. 27-34. (In Russ.)]
  3. Глушков А.Н., Поленок Е.Г., Гордеева Л.А., Мун С.А., Костянко М.В., Антонов А.В., Титов В.А., Вержбицкая Н.Е., Вафин И.А. Иммунологический дисбаланс при раке молочной железы и раке легкого у женщин в постменопаузе // Медицинская иммунология, 2018. Т. 20, № 6. С. 927-934. [Glushkov A.N., Polenok E.G., Gordeeva L.A., Mun S.A., Kostyanko M.V., Antonov A.V., Titov V.A., Verzhbitskaya N.E., Vafin I.A. Immunological imbalance in breast cancer and lung cancer in postmenopausal women. Meditsinskaya immunologiya = Medical Immunology (Russia), 2018, Vol. 20, no. 6, pp. 927-934. (In Russ.)] doi: 10.15789/1563-0625-2018-6-927-934.
  4. Глушков А.Н., Поленок Е.Г., Костянко М.В., Титов В.А., Вафин И.А., Рагожина С.Е. Взаимное влияние антител к бензо[a]пирену, эстрадиолу и прогестерону на риски возникновения рака легкого // Российский иммунологический журнал, 2015. Т. 9 (18), № 3. С. 343-349. [Glushkov A.N., Polenok E.G., Kostyanko M.V., Titov V.A., Vafin I.A., Ragozhina S.E. Mutual effects of antibodies to benzo[a]pyrene, estradiol and progesterone on the lung cancer risks. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2015, Vol. 9 (18), no. 3, pp. 343-349. (In Russ.)]
  5. Глушков А.Н., Поленок Е.Г., Магарилл Ю.А., Аносова Т.П., Антонов А.В., Вержбицкая Н.Е. Антитела к бензо[а]пирену, эстрадиолу и прогестерону у больных раком молочной железы в постменопаузе // Сибирский онкологический журнал, 2016. Т. 15, № 6. С. 28-34. [Glushkov A.N., Polenok E.G., Magarill Yu.A., Anosova T.P., Antonov A.V., Verzhbitskaya N.E. Antibodies to benzo[a]pyrene, estradiol, and progesterone in postmenopausal breast cancer patients. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology, 2016, Vol. 15, no. 6, pp. 28-34. (In Russ.)]
  6. Глушков А.Н., Поленок Е.Г., Мун С.А., Гордеева Л.А., Костянко М.В., Антонов А.В., Вержбицкая Н.Е., Вафин И.А. Индивидуальный иммунологический фенотип и риск рака молочной железы у женщин в постменопаузе // Российский иммунологический журнал, 2019. Т. 13, № 1. С. 44-52. [Glushkov A.N., Polenok E.G., Mun S.A., Gordeeva L.A., Kostyanko M.V., Antonov A.V., Verzhbitskaya N.E., Vafin I.A. Personal immunological phenotype and breast cancer risk in postmenopausal women. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2019, Vol. 13, no. 1, pp. 44-52. (In Russ.)]
  7. Глушков А.Н., Поленок Е.Г., Мун С.А., Гордеева Л.А., Костянко М.В., Колпинский Г.И., Луценко В.А., Антонов А.В., Титов В.А., Вафин И.А. Антитела к химическим канцерогенам и половым стероидам и содержание эстрадиола и прогестерона в сыворотке крови женщин больных раком молочной железы и мужчин больных раком легкого // Российский иммунологический журнал, 2020. Т. 23, № 1. С. 69-78. [Glushkov A.N., Polenok E.G, Mun S.A., Gordeeva L.A., Kostyanko M.V., Kolpinsky G.I., Lutsenko V.A., Antonov A.V., Titov V.A., Vafin I.A. Antibodies to the chemical carcinogens and sex steroids of estradiol and progesterone the serum levels of features in women and men with breast and lung cancer. Rossiyskiy immunologicheskiy zhurnal = Russian Journal of Immunology, 2020, Vol. 23, no. 1, pp. 69-78. (In Russ.)]
  8. Гуляева Л.Ф., Вавилин В.А., Ляхович В.В. Ферменты биотрансформации ксенобиотиков в химическом канцерогенезе. Новосибирск: ГПНТБ СО РАН, 2000. 85 с. [Gulyaeva L.F., Vavilin V.A., Lyakhovich V.V. Biotransformation enzymes of xenobiotics in chemical carcinogenesis]. Novosibirsk: GPNTB SBRAS, 2000. 85 p. (In Russ.)
  9. Давыдов М.И., Богуш Т.А., Полоцкий Б.Е., Тюляндин С.А. Эстрогеновые рецепторы β – новая мишень в терапии немелкоклеточного рака легкого // Вестник РАМН, 2012. Т. 67, № 2. С. 16-22. [Davidov M.I., Bogush T.A., Polotskiy B.E., Tylyandin S.A. Estrogen receptors β – new target in cellular lung cancer treatment. Vestnik RAMN = Annals of the Russian Academy of Medical Sciences, 2012, Vol. 67, no. 2, pp. 16-22. (In Russ.)]
  10. Имянитов Е.Н., Хансон К.П. Молекулярная онкология: клинические аспекты. Санкт-Петербург: Издательский дом СПбМАПО, 2007. 211 с. [Imyanitov E.N., Hanson K.P. Molecular Oncology: Cinical aspects]. St. Petersburg: Publishing house of St. Petersburg Medical Academy of Postgraduate Education, 2007, 211 p.
  11. Состояние онкологической помощи населению России в 2019 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 239 с. [State of cancer care in Russia in 2019. Ed. Kaprin A.D., Starinskiy V.V., Shachzodova A.O.] Moscow: P. Herzen Moscow Oncology Research Institute − Branch of National Medical Radiology Research Center, 2020. 239 p.
  12. Суханов В.А., Пирузян Л.А. Роль физиологических факторов в прогнозировании риска развития онкологических заболеваний на основе полиморфизма системы ферментов метаболизма ксенобиотиков // Физиология человека, 2010. Т. 36, № 6. С. 122-137. [Sukhanov V.A., Piruzyan L.A. Role of physiological factors in predicting the risk of oncological diseases on the basis of the polymorphism of the xenobiotic metabolism enzyme system. Fiziologiya cheloveka = Human Physiology, 2010, Vol. 36, no. 6, pp. 723-736. (In Russ.)]
  13. Худолей В.В. Канцерогены: характеристики, закономерности, механизмы действия // Исследования по генетике, 1999. №12. С. 67-85. [Khudoley V.V. Carcinogens: characteristics, patterns, mechanisms of action. Issledovaniya po genetike = Research on Genetics, 1999, no. 12, pp. 67-85. (In Russ.)]
  14. Худолей В.В., Мизгирев И.В. Экологически опасные факторы. СПб.: Publishing House, 1996. 184 с. [Khudoley V.V., Mizgirev I.V. Environmentally dangerous factors]. St. Petersburg: Publishing House, 1996. 184 p.
  15. Шашова Е.Е., Кондакова И.В., Слонимская Е.М., Глущенко С.А. Сравнительное изучение содержания рецепторов эстрогенов и прогестерона в неизмененной, опухолевой и метастатической тканях при раке молочной железы // Сибирский онкологический журнал, 2008. Т. 4, № 28. С. 42-45. [Shashova E.E., Kondakova I.V., Slonimskaya E.M., Gluschenko S.A. Comparative study of the levels of estrogen and progesteron receptors in normal, tumor and metastatic tissues of breast cancer patients. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology, 2008, Vol. 4, no. 28, pp. 42-45. (In Russ.)]
  16. Agudo A., Peluso M., Munnia A., Luján-Barroso L., Sánchez M.J., Molina-Montes E., Sánchez-Cantalejo E., Navarro C., Tormo M.J., Chirlaque M.D., Barricarte A., Ardanaz E., Amiano P., Dorronsoro M., Quirós J.R., Piro S., Bonet C., Sala N., González C.A. Aromatic DNA adducts and risk of gastrointestinal cancers: a case-cohort study within the EPIC-Spain. Cancer Epidemiol. Biomarkers Prev., 2012, Vol. 21, no. 4, pp. 685-692.
  17. Al-Saleh I., Arif J., El-Doush I., Al-Sanea N., Jabbar A.A., Billedo G., Shinwari N., Mashhour A., Mohamed G.. Carcinogen DNA adducts and the risk of colon cancer: case-control study. Biomarkers, 2008, Vol. 13, no. 2, pp. 201-216.
  18. Androutsopoulos V.P., Tsatsakis A.M., Spandidos D.A. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer, 2009, Vol. 9, 187. doi: 10.1186/1471-2407-9-187.
  19. Blaszczyk E., Mielżyńska-Švach D. Polycyclic aromatic hydrocarbons and PAH-related DNA adducts. J. Appl. Genet., 2017, Vol. 58, no. 3, pp. 321-330.
  20. Bochskanl R., Thie M., Kirchner C.J. Active immunization of rabbits against progesterone: increase in hormone levels, and changes in metabolic clearance rates and in genital tract tissues. Steroid Biochem., 1989, Vol. 33, no. 3, pp. 349-355.
  21. Borska L., Andrys C., Krejsek J., Palicka V., Chmelarova M., Hamakova K., Kremlacek J., Borsky P., Fiala Z. Serum level of antibody against benzo[a]pyrene-7,8-diol-9,10-epoxide-DNA adducts in people dermally exposed to PAHs. J. Immunol. Res., 2014, 834389. doi: 10.1155/2014/834389.
  22. Bouchardy C., Benhamo S., Schaffar R., Verkooijen H.M., Fioretta G., Schubert H., Vinh-Hung V., Soria J.C., Vlastos G., Rapiti E. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer, 2011, Vol. 117, no. 6, pp. 1288-1295.
  23. Caldwell B.V., Tillson S.A., Esber H., Thorneycroft I.H. Survival of tumors after immunization against oestrogens. Nature, 1971, Vol. 231, no. 5298, pp. 118-119.
  24. Cavalieri E.L., Rogan E.G. Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention. Clin. Transl. Med., 2016, Vol. 5, 12. doi: 10.1186/s40169-016-0088-3.
  25. Cavalieri E.L., Rogan E.G., Zahid M. Critical depurinating DNA adducts: Estrogen adducts in the etiology and prevention of cancer and dopamine adducts in the etiology and prevention of Parkinson’s disease. Int. J. Cancer., 2017, Vol. 141, no. 6, pp. 1078-1090.
  26. Ceppi M., Munnia A., Cellai F., Bruzzone M., Peluso M.E.M. Linking the generation of DNA adducts to lung cancer. Toxicology, 2017, no. 390, pp. 160-166.
  27. Černohorská H., Klimešová S., Lepša L., Jinoch P., Milcová A., Schmuczerová J., Topinka J., Lábaj J. Influence of immunization with non-genotoxic PAH-KLH conjugates on the resistance of organisms exposed to benzo[a]pyrene. Mut. Res., 2012, Vol. 742, no.1-2, pp. 2-10.
  28. Chagnaud J.L., Faiderbe S., Geffard M. Identification and immunochemical characterization of IgA in sera of patients with mammary tumors. Int. J. Cancer, 1992, Vol. 50, no. 3, pp. 395-401.
  29. Chagnaud J.L., Faiderbe S., Geffard M. Effects of monoclonal anti-idiotypic antibody, internal image of benzo(a)pyrene on sarcoma in rats. C.R Acad. Sci III., 1993, Vol. 316, no. 10, pp. 1266-1269. (In French)
  30. Charles G.D., Bartles M.J., Zacharewski T.R., Gollapudi B.B., Freshour N.L., Carney E.W. Activity of benzo[a]pyrene and its hydroxylated metabolites in an estrogen receptor-alpha reporter gene assay. Toxicol. Sci., 2000, Vol. 55, no. 2, pp. 320-326.
  31. Chen Z., Zhang Y., Yang J., Jin M., Wang X.W., Shen Z.Q., Qiu Z., Zhao G., Wang J., Li J.W. Estrogen promotes benzo[a]pyrene-induced lung carcinogenesis through oxidative stress damage and cytochrome c-mediated caspase-3 activation pathway in female mice. Cancer. Lett., 2011, Vol. 308, no. 1, pp. 14-22.
  32. Counihan K.A., Vertosick F.T., Kelly R.H. Anti-estrogen antibodies in systemic lupus erythematosus: a quantitative evaluation of serum levels. Immunol. Invest., 1991, Vol. 20, no. 3, pp. 317-331.
  33. Curtis G.L., Ryan W.L., Stenbäck F. Antibody stimulation of benzo[a]pyrene carcinogenesis. Cancer Lett., 1978, Vol. 4, no. 4, pp. 223-228.
  34. de Buck S.S., Augustijns P., Muller C.P. Specific antibody modulates absorptive transport and metabolic activation of benzo[a]pyrene across Caco-2 monolayers. J. Pharmacol. Experim. Therap., 2005, Vol. 313, no. 2, pp. 640-646.
  35. de Buck S.S., Muller C.P. Immunopropylactic approaches against chemical carcinogenesis. Vaccine, 2005, Vol. 23, no. 17-18, pp. 2403-2406.
  36. Fertuck K.C., Matthews J.B., Zacharewski T.R. Hydroxylated benzo[a]pyrene metabolites are responsible for in vitro estrogen receptor-mediated gene expression induced by benzo[a]pyrene, but do not elicit uterotrophic effects in vivo. Toxicol Sci., 2001, Vol. 59, no. 2, pp. 231-240.
  37. Franks W.R., Creech H.J. Chemoantigens and carcinogenesis: I. Canсer Res., 1939, Vol. 35, no. 2, pp. 203-212.
  38. Galati R., Crebelli R., Zijno A., Conti L., Falasca G., Verdina A. The effect of humoral immunity against adducted benzo[a]pyrene on DNA damage elicited by acute carcinogen exposure in Swiss mice. In vivo, 2000, Vol. 14, no. 6, pp. 747-751.
  39. Galati R., Zijno A., Crebelli R., Falasca G., Tomei F., Iecher F., Carta P., Verdina A. Defection of antibodies to benzo[a]pyrene diol epoxide-DNA adducts in sera from individuals exposed to low doses of polycyclic aromatic hydrocarbons. J. Exp. Clin. Cancer Res., 2001, Vol. 20, no. 3, pp. 359-364.
  40. Glushkov A.N. Immunological disbalance in carcinogenesis. Med. Hypotheses, 2014, Vol. 83, no. 2, pp. 166-171.
  41. Glushkov A.N., Polenok E.G. Immunomodulation of carcinogens-induced steroids-dependent human diseases. Saudi J. Biol. Sci., 2019, Vol. 26, no. 2, pp. 244-251.
  42. Glushkov A.N., Polenok E.G., Mun S.A., Gordeeva L.A. Immunization against environmental chemical carcinogens: pro and contra. Med. Hypotheses, 2019, Vol. 131, 109303. doi: 10.1016/j.mehy.2019.109303.
  43. Glushkov A.N., Polenok E.G., Mun S.A., Gordeeva L.A. Inversion of natural immuno-hormonal interactions under influence of antibodies against environmental chemical carcinogens. Med. Hypotheses, 2020, Vol. 144, 109981. doi: 10.1016/j.mehy.2020.109981.
  44. Go R.E., Hwang K.A., Choi K.C. Cytochrome P450 1 family and cancers. J. Steroid Biochem. Mol. Biol., 2015, Vol. 147, pp. 24-30.
  45. Grigoryeva E.S., Kokova D.A., Gratchev A.N., Cherdyntsev E.S., Buldakov M.A., Kzhyshkowska J.G., Cherdyntseva N.V. Smoking-related DNA adducts as potential diagnostic markers of lung cancer: new perspectives. Exp. Oncol., 2015, Vol. 37, no. 1, pp. 5-12.
  46. Grova N., Prodhomme E.J., Schellenberger M.T., Farinelle S., Muller C.P. Modulation of carcinogen bioavailability by immunisation with benzo[a]pyrene – conjugate vaccines. Vaccine, 2009, Vol. 27, no. 31, pp. 4142-4151.
  47. Gunter M.J., Divi R.L., Kulldorff M., Vermeulen R., Haverkos K.J., Kuo M.M., Strickland P., Poirier M.C., Rothman N., Sinha R. Leukocyte polycyclic aromatic hydrocarbon-DNA adduct formation and colorectal adenoma. Carcinogenesis, 2007, Vol. 28, no. 7, pp. 1426-1429.
  48. Harris C.C., Vahakangas K., Newman M.J., Trivers G.E., Shamsuddin A., Sinopoli N., Mann D.L., Wright W.E. Detection of benzo[a]pyrene diol epoxide-DNA adducts in peripheral blood lymphocytes and antibodies to the adducts in serum from coke oven workers. Proc. Natl Acad. Sci. USA, 1985, Vol. 82, no. 19, pp. 6672-6676.
  49. Haugen A., Becher G., Benestad C., Vahakangas K., Trivers G.E., Newman M.J., Harris C.C. Determination of polycyclic aromatic hydrocarbons in the urine, benzo(a)pyrene diol epoxide-DNA adducts in lymphocyte DNA, and antibodies to the adducts in sera from coke oven workers exposed to measured amounts of polycyclic aromatic hydrocarbons in the work atmosphere. Cancer Res., 1986, Vol. 46, no. 8, pp. 4178-4183.
  50. Hillier S.G., Groom G.V., Boyns A.R., Cameron E.H. Effects of active immunisation against steroids upon circulating hormone concentrations. J. Steroid Biochem., 1975, Vol. 6, no. 3-4, pp. 529-535.
  51. Hsu T.M., Zhang Y.J., Santella R.M. Immunoperoxidase quantitation of 4-aminobiphenyl- and polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral and urothelial cells of smokers and nonsmokers. Cancer Epidemiol. Biomarkers. Prev., 1997, Vol. 6, no. 3, pp. 193-199.
  52. Jacobson J.S., Begg M.D., Wang L.W., Wang Q., Agarwal M., Norkus E., Singh V.N., Young T.L., Yang D., Santella R.M. Effects of a 6-month vitamin intervention on DNA damage in heavy smokers. Cancer Epidemiol. Biomarkers Prev., 2000, Vol. 9, no. 12, pp. 1303-1311.
  53. Jeffy B.D., Chirnomas R.B., Romagnolo D.F. Epigenetics of breast cancer: polycyclic aromatic hydrocarbons as risk factors. Environ. Mol. Mutagen., 2002, Vol. 39, no. 2-3, pp. 235-244.
  54. Jonsson C., Stål P., Sjöqvist U., Akerlund J.E., Löfberg R., Möller L. DNA adducts in normal colonic mucosa from healthy controls and patients with colon polyps and colorectal carcinomas. Mutagenesis, 2010, Vol. 25, no. 5, pp. 499-504.
  55. Käfferlein H.U., Marczynski B., Mensing T., Brüning T. Albumin and hemoglobin adducts of benzo[a]pyrene in humans – Analytical methods, exposure assessment, and recommendations for future directions. Crit. Rev. Toxicol., 2010, Vol. 40, no. 2, pp. 126-150.
  56. Kang S.C., Lee B.M. Effect of estrogen receptor (ER) on benzo[a]pyrene-DNA adduct formation in human breast cancer cells. J. Toxicol. Environ. Health A., 2005, Vol. 68, no. 21, pp. 1833-1840.
  57. Lin S., Lin C.J., Hsieh D.P., Li L.A. ERα phenotype, estrogen level, and benzo[a]pyrene exposure modulate tumor growth and metabolism of lung adenocarcinoma cells. Lung Cancer, 2012, Vol. 75, no. 3, pp. 285-292.
  58. Martin T.E., Henricks D.M., Hill J.R. Jr, Rawlings N.C. Active immunization of the cow against oestradiol-17beta. J. Reprod. Fertil., 1978, Vol. 53, no. 1, pp. 173-178.
  59. Maselli A., Capoccia S., Pugliese P., Raggi C., Cirulli F., Fabi A., Malorni W., Pierdominici M., Ortona E. Autoantibodies specific to estrogen receptor alpha act as estrogen agonists and their level correlate with breast cancer cell proliferation. Oncoimmunology, 2016, Vol. 5, no. 2, e1074375-2. doi: 10.1146/annurev-cancerbio-050216-122002.
  60. McCreery M.Q., Balmain A. Chemical carcinogenesis models of cancer: back to the future. Annu. Rev. Cancer. Biol., 2017, Vol. 1, pp. 295-312.
  61. Mohammed H., Russell I.A., Stark R., Rueda O.M., Hickey T.E., Tarulli G.A., Serandour A.A., Birrell S.N., Bruna A., Saadi A., Menon S., Hadfield J., Pugh M., Raj G.V., Brown G.D., D’Santos C., Robinson J.L., Silva G., Launchbury R., Perou C.M., Stingl J., Caldas C., Tilley W.D., Carroll J.S. Progesterone receptor modulates ERα action in breast cancer. Nature, 2015, Vol. 523, no. 7560, pp. 313-317.
  62. Moolten F.L., Capparel N., Boger E. Reduction of respiratory tract binding of benzo(a)pyrene in mice by immunization. J. Natl Cancer Inst., 1978, Vol. 61, no. 5, pp. 1347-1349.
  63. Moolten F.L., Schreiber B., Rizzone A., Weiss A.J., Boger E. Protection of mice against 7,12-dimethylbenz(a)anthracene – induced skin tumors by immunization with a fluorinated analog of the carcinogen. Cancer Res., 1981, Vol. 41, no. 2, pp. 425-429.
  64. Newman M.J., Light B.A., Weston A., Tollurud D., Clark J.L., Mann D.L., Blackmon J.P., Harris C.C. Detection and characterization of human serum antibodies to polycyclic aromatic hydrocarbon diol-epoxide DNA adducts. J. Clin. Invest., 1988, Vol. 82, no. 1, pp. 145-153.
  65. Nock N.L., Tang D., Rundle A., Neslund-Dudas C., Savera A.T., Bock C.H., Monaghan K.G., Koprowski A., Mitrache N., Yang J.J., Rybicki B.A. Associations between smoking, polymorphisms in polycyclic aromatic hydrocarbon (PAH) metabolism and conjugation genes and PAH-DNA adducts in prostate tumors differ by race. Cancer Epidemiol. Biomarkers Prev., 2007, Vol. 16, no. 6, pp. 1236-1245.
  66. Ortona E., Pierdominici M., Berstein L. Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer. J. Steroid Biochem. Mol. Biol., 2014, 144, Pt B, pp. 260-267.
  67. Pauk N., Klimesova S., Kara J., Topinka J., Labaj J. The relevance of monitoring of antibodies against polycyclic aromatic hydrocarbon (PAH) and PAH-DNA adducts in serum in relation to lung cancer and chronic obstructive pulmonary disease (COPD). Neoplasma, 2013, Vol. 60, no. 2, pp. 182-187.
  68. Peck R.M., Peck E.B. Inhibition of chemically induced neoplasia by immunization with an antigenic carcinogen- protein conjugate. Cancer Res., 1971, Vol. 31, pp. 1550-1554.
  69. Peluso M., Munnia A., Hoek G., Krzyzanowski M., Veglia F., Airoldi L., Autrup H., Dunning A., Garte S., Hainaut P., Malaveille C., Gormally E., Matullo G., Overvad K., Raaschou-Nielsen O., Clavel-Chapelon F., Linseisen J., Boeing H., Trichopoulou A., Trichopoulos D., Kaladidi A., Palli D., Krogh V., Tumino R., Panico S., Bueno-De-Mesquita H.B., Peeters P.H., Kumle M., Gonzalez C.A., Martinez C., Dorronsoro M., Barricarte A., Navarro C., Quiros J.R., Berglund G., Janzon L., Jarvholm B., Day N.E., Key T.J., Saracci R., Kaaks R., Riboli E., Vineis P. DNA adducts and lung cancer risk: a prospective study. Cancer Res., 2005, Vol. 65, no. 17, pp. 8042-8048.
  70. Petruzzelli S., Celi A., Pulerà N., Baliva F., Viegi, G., Carrozzi L., Ciacchini G., Bottai M., Di Pede F., Paoletti P., Giuntini C. Serum antibodies to benzo[a]pyrene diol epoxide-DNA adducts in the general population: effects of air pollution, tobacco smoking, and family history of lung diseases. Cancer Res., 1998, Vol. 58, no. 18, pp. 4122-4126.
  71. Pfohl-Leszkowicz A., Grosse Y., Carrière V., Cugnenc P.H., Berger A., Carnot F., Beaune P., de Waziers I. High levels of DNA adducts in human colon are associated with colorectal cancer. Cancer Res., 1995, Vol. 55, no. 23, pp. 5611-5616.
  72. Phillips D.H. Smoking-related DNA and protein adducts in human tissues. Carcinogenesis, 2002, Vol. 23, no. 12, pp. 1979-2004.
  73. Pulerà N., Retruzzelli S., Celi A., Puntoni R., Fornai E., Säwe U., Paoletti P., Giuntini C. Presence and persistence of serum anti-benzo[a]pyrene diolepoxide-DNA adduct antibodies in smokers: effects of smoking reduction and cessation. Int. J. Cancer, 1997, Vol. 70, no. 2, pp. 145-149.
  74. Rasmussen M.V., Silbart L.K. Peroral administration of specific antibody enhances carcinogen excretion. J. Immunother., 1998, Vol. 21, no. 6, pp. 418-426.
  75. Rawlings N.C., Kennedy S.W., Henricks D.M. The active immunization of the cyclic ewe against an estrone protein conjugate. Theriogenology, 1979, Vol. 12, no. 3, pp. 139-151.
  76. Ronco A.L., de Stefani E., Correa P., Deneo-Pellegrini H., Boffetta P., Acosta G., Mendilaharsu M. Dietary benzo[a]pyrene, alcohol drinking, and risk of breast cancer: a case-control study in Uruguay. Asian Pac. J. Cancer Prev., 2011, Vol. 12, no. 6, pp. 1463-1467.
  77. Rosenberg M., Amir D., Folman Y. The effect of active immunization against progesterone on plasma concentrations of total and free progesterone, estradiol-17beta and LH in the cyclic ewe. Theriogenology, 1987, Vol. 28, no. 4, pp. 417-426.
  78. Rundle A., Richards C., Neslund-Dudas C., Tang D., Rybicki B.A. Neighborhood socioeconomic status modifies the association between individual smoking status and PAH-DNA adduct levels in prostate tissue. Environ Mol. Mutagen., 2012, Vol. 53, no. 5, pp. 384-391.
  79. Rybicki B.A., Neslund-Dudas C., Bock C.H., Rundle A., Savera A.T., Yang J.J., Nock N.L., Tang D. Polycyclic aromatic hydrocarbon – DNA adducts in prostate and biochemical recurrence after prostatectomy. Clin. Cancer Res., 2008, Vol. 14, no. 3, pp. 750-757.
  80. Sadikovic B., Rodenhiser D.I. Benzopyrene exposure disrupts DNA methylation and growth dynamics in breast cancer cells. Toxicol. Appl. Pharmacol., 2006, Vol. 216, no. 3, pp. 458-468.
  81. Sagiv S.K., Gaudet M.M., Eng S.M., Abrahamson P.E., Shantakumar S., Teitelbaum S.L., Bell P., Thomas J.A., Neugut A.I., Santella R.M., Gammon M.D. Polycyclic aromatic hydrocarbon-DNA adducts and survival among women with breast cancer. Environ. Res., 2009, Vol. 109, no. 3, pp. 287-291.
  82. Santella R.M., Gammon M.D., Zhang Y.J., Motykiewicz G., Young T.L., Hayes S.C., Terry M.B., Schoenberg J.B., Brinton L.A., Bose S., Teitelbaum S.L., Hibshoosh H. Immunohistochemical analysis of polycyclic aromatic hydrocarbon-DNA adducts in breast tumor tissue. Cancer Lett., 2000, Vol. 154, no. 2, pp. 143-149.
  83. Santella R.M., Perera F.P., Young T.L., Zhang Y.J., Chiamprasert S., Tang D., Wang L.W., Beachman A., Lin J.H., DeLeo V.A. Polycyclic aromatic hydrocarbon-DNA and protein adducts in coal tar patients and controls and their relationship to glutathione S-transferase genotype. Mutat. Res., 1995. Vol. 334, no. 2, pp. 117-124.
  84. Schellenberger M.T., Farinelle S., Willième S., Muller C.P. Evaluation of adjuvants for a candidate conjugate vaccine against benzo[a]pyrene. Hum. Vaccin., 2011, Vol. 7, no. 1, pp. 166-173.
  85. Sestak I. Preventative therapies for healthy women at high risk of breast cancer. Cancer Manag. Res., 2014, Vol. 6, pp. 423-430.
  86. Siegel R.L., Miller K.D., Jemal A. Cancer Statistics, 2020. C. A. Cancer J. Clin., 2020, Vol. 70, no. 1, pp. 7-30.
  87. Silbart L.K., Keren D.F. Reduction of intestinal carcinogen absorption by carcinogen-specific immunity. Science, 1989, Vol. 243, no. 4897, pp. 1462-1464.
  88. Silbart L.K., McAller F., Rasmussen M.V., Goslinoski L., Keren D.F., Finley A., Van Kruiningen H.J., Winchell J.M. Selective induction of mucosal immune responses to 2-acetylaminofluorene. Anticancer Res., 1996, Vol. 16, no. 2, pp. 651-660.
  89. Silbart L.K., Rasmussen H.V., Oliver A.R. Immunoprophylactic intervention in chemical toxicity and carcinogenicity. Vet. Hum. Toxicol., 1997, Vol. 39, no. 1, pp. 37-43.
  90. Tang D., Kryvenko O.N., Wang Y., Jankowski M., Trudeau S., Rundle A., Rybicki B.A. Elevated polycyclic aromatic hydrocarbon-DNA adducts in benign prostate and risk of prostate cancer in African Americans. Carcinogenesis, 2013, Vol. 34, no. 1, pp. 113-120.
  91. Vogel V.G. Role of hormones in cancer prevention. ASCO Educational Book, 2014, Vol. 34, pp. 34-40.
  92. Weston A., Rowe M., Poirier M., Trivers G., Vahakangas K., Newman M., Haugen A., Manchester D., Mann D., Harris C. The application of immunoassays and fluorometry to the detection of polycyclic hydrocarbon-macromolecular adducts and anti-adduct antibodies in humans. Int. Arch. Occup. Environ. Health, 1988, Vol. 60, no. 3, pp. 157-62.
  93. Wiencke J.K., Kelsey K.T., Varkonyi A., Semey K., Wain J.C., Mark E., Christiani D.C. Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. Cancer Res., 1995, Vol. 55, no. 21, pp. 4910-4914.
  94. Yager J.D. Mechanisms of estrogen carcinogenesis: The role of E2/E1 – quinone metabolites suggests new approaches to preventive intervention – A review. Steroids, 2015, Vol. 99b (Pt A), pp. 56-60.
  95. Zhang Y.J., Weksler B.B., Wang L., Schwartz J., Santella R.M. Immunohistochemical detection of polycyclic aromatic hydrocarbon-DNA damage in human blood vessels of smokers and non-smokers. Atherosclerosis, 1998, Vol. 140, no. 2, pp. 325-331.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure 1. Frequency (%) of revealing immunological phenotypes (A, protective; B and C, compensatory, D, procarcinogenic) in healthy women and breast cancer patients [6]

Download (204KB)
3. Figure 2. Individual blood serum ratios Pg/Es in healthy women with different immunological phenotypes (A, protectiv; B and C, compensatory; D, procancerogenic) and breast cancer patients (BCP) [7]

Download (86KB)
4. Figure 3. Correlations between blood serum Es (A) and Pg (B) concentrations and IgA-Es and IgA-Pg levels in healthy women with low (1) and high (2) IgA-Bp levels [43]

Download (202KB)
5. Figure 4. Frequency (%) of high individual IgA-Es/IgA-Pg ratio in breast cancer patients with I and II-IV tumor stages according to ER/PR status

Download (256KB)

Copyright (c) 2022 Glushkov A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies